Last reviewed · How we verify
Deciphera Pharmaceuticals, LLC — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| DCC-2618 | DCC-2618 | phase 3 | Tyrosine kinase inhibitor | KIT, PDGFRA | Oncology |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Akeso · 1 shared drug class
- Angion Biomedica Corp · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Beijing InnoCare Pharma Tech Co., Ltd. · 1 shared drug class
- Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
- Centre Leon Berard · 1 shared drug class
- Chang-Ming Huang, Prof. · 1 shared drug class
- AB Science · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Deciphera Pharmaceuticals, LLC:
- Deciphera Pharmaceuticals, LLC pipeline updates — RSS
- Deciphera Pharmaceuticals, LLC pipeline updates — Atom
- Deciphera Pharmaceuticals, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Deciphera Pharmaceuticals, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/deciphera-pharmaceuticals-llc. Accessed 2026-05-14.